CP
RIGL icon

CenterBook Partners’s Rigel Pharmaceuticals RIGL Stock Holding History

CenterBook Partners’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.29M Buy
+109,575
New +$3.38M 0.21% 121

Other funds holding RIGL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

CenterBook Partners's RIGL Position: Q2 2026 in Review

CenterBook Partners opened a new position in Rigel Pharmaceuticals (RIGL) in Q2 2026: 109,575 shares worth $4.29M. The stake represents 0.21% of the portfolio and ranks #121 among its holdings.

64 funds tracked by Wall St. Rank hold RIGL as of Q2 2026.

  • CenterBook Partners held 109,575 shares of Rigel Pharmaceuticals worth $4.29M as of Q2 2026.
  • Rigel Pharmaceuticals was a new CenterBook Partners position in Q2 2026.
  • Rigel Pharmaceuticals made up 0.21% of CenterBook Partners's portfolio in Q2 2026, its #121 holding.
  • 64 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2026.

Based on CenterBook Partners's 13F filing for Q2 2026, filed 11 Aug 2026.